scutellarin

see scutellarein for aglycone

Also Known As:

beta-D-glucopyranosiduronic acid, 5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl; flavone, 4',5,6,7-tetrahydroxy-, 7-beta-D-glucopyranuronoside; scutellarein 7-O-beta-D-glucuronide; scutellarein 7-beta-D-glucuronide; scutellarein 7-beta-D-glucuronoside; scutellarein 7-glucuronide; scutellarein-7-O-beta-glucuronide; scutellarein-7-O-glucuronide; scutellarin B

Networked: 246 relevant articles (44 outcomes, 77 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Chen, Li: 9 articles (02/2022 - 01/2017)
2.	Wang, Ting-Hua: 7 articles (01/2022 - 01/2019)
3.	Yuan, Yun: 7 articles (01/2020 - 11/2014)
4.	Li, Nian-Guang: 7 articles (12/2018 - 09/2012)
5.	Zhang, Wei: 6 articles (04/2022 - 01/2015)
6.	Gu, Ting: 6 articles (12/2018 - 01/2015)
7.	Ling, Eng-Ang: 6 articles (01/2017 - 11/2014)
8.	Li, Yongjun: 5 articles (01/2022 - 09/2016)
9.	Xiong, Liu-Lin: 5 articles (10/2021 - 01/2019)
10.	Dong, Ze-Xi: 5 articles (12/2018 - 04/2015)

Related Diseases

1.	Ischemia 04/01/2023 - "Scutellarin ameliorates ischemia/reperfusion injury‑induced cardiomyocyte apoptosis and cardiac dysfunction via inhibition of the cGAS‑STING pathway." 11/01/2019 - "Scutellarin administration following bilateral hind limb ischemia-reperfusion significantly ameliorated all studied parameters. " 11/01/2019 - "Twenty-four adult male albino rats were equally divided into four groups; control, scutellarin, bilateral hind limb ischemia-reperfusion, and bilateral hind limb ischemia-reperfusion followed by scutellarin (at a dose of 20 mg/kg/day for 14 days). " 11/01/2019 - "This study aimed to investigate the role of scutellarin in ameliorating lung injury in a rat model of bilateral hind limb ischemia-reperfusion. " 01/01/2021 - "ERRATUM: Effect of Scutellarin on Neurogenesis in Neonatal Hypoxia-Ischemia Rat Model: Potential Mechanisms of Action."
2.	Brain Ischemia (Cerebral Ischemia) 12/01/2022 - "Scutellarin alleviates cerebral ischemia/reperfusion by suppressing oxidative stress and inflammatory responses via MAPK/NF-κB pathways in rats." 01/01/2020 - "Scutellarin, an herbal compound, can effectively suppress the inflammatory response in activated microglia/brain macrophage(AM/BM) in experimentally induced cerebral ischemia; however, the underlying mechanism for this has not been fully clarified. " 01/01/2020 - "Scutellarin Exerts Anti-Inflammatory Effects in Activated Microglia/Brain Macrophage in Cerebral Ischemia and in Activated BV-2 Microglia Through Regulation of MAPKs Signaling Pathway." 08/01/2018 - "However, the mechanisms by which scutellarin mediates neuroprotection in cerebral ischemia remain unclear. " 01/01/2017 - "This review highlights some of our recent findings taking into consideration of others demonstrating the beneficial effects of scutellarin on both glial cell types in cerebral ischemia as manifested by improvement of neurological functions."
3.	Hypoxia (Hypoxemia) 11/29/2019 - "Our results showed that scutellarin improved cell viability in hepatocytes exposed to hypoxia/reoxygenation (H/R). " 12/01/2019 - "Moreover, Scutellarin significantly reversed hypoxia-promoted epithelial-mesenchymal transition (EMT) in BC cells and the PI3K/Akt and MAPK pathways were implicated in the suppressive effect. " 11/29/2019 - "Scutellarin attenuates hypoxia/reoxygenation injury in hepatocytes by inhibiting apoptosis and oxidative stress through regulating Keap1/Nrf2/ARE signaling." 01/01/2018 - "Scutellarin inhibited the expression of NLRP3 in vitro (the hypoxia + EBHM group/normal control group ratio versus the hypoxia model group/normal control group ratio: 2.30±0.12 versus 4.06±0.19, p<0.01) and in vivo (the HIOP + EBHM group/normal control group ratio versus the HIOP model group/normal control ratio: 3.39±0.42 versus 6.07±0.22, p<0.01). " 01/01/2018 - "In the in vitro cell viability experiments, 50 µM scutellarin statistically significantly enhanced the viability rate when compared to 2 µM and 10 µM scutellarin (hypoxia + 50 µM EBHM group: 94.01±2.130% and 86.02±2.520% after 24 and 48 h, respectively; hypoxia model group: 74.98±3.860% and 64.41±4.890% after 24 and 48 h, respectively; for all when compared to normal control, p<0.001). "
4.	Inflammation (Inflammations) 11/13/2020 - "However, overexpression of NLRP3 eliminated the anti-inflammation and anti-EMT functions of scutellarin in vitro. " 11/13/2020 - "In this study, scutellarin suppressed BLM-induced inflammation via NF-κB/NLRP3 pathway both in vivo and in vitro. " 10/01/2017 - "The results of the current study suggest a novel effect of scutellarin involving the inhibition of TLR4/NF‑κB‑mediated inflammation." 10/01/2017 - "The present study demonstrated that scutellarin prevented CIA, and inhibited the expression of inflammation factors, IL‑1β, IL‑6 and TNF‑α. " 01/01/2022 - "Scutellarin, an active ingredient extracted from Erigeron breviscapus (Vaniot) Ha, Hand-Mazz, is reported to exhibit therapeutic potential in several degenerative diseases by suppressing inflammation and regulating metabolism. "
5.	Neuroinflammatory Diseases 11/20/2021 - "Collectively, these results suggest that scutellarin ameliorates depression-like behaviors induced by neuroinflammation partially through inhibiting the TLR4/NF-κB pathway in astrocytes." 01/01/2022 - "This study found that scutellarin improved Aβ pathology, neuroinflammation, and cognitive deficits in APP/PS1 mice. " 11/20/2021 - "In present study, it was found that scutellarin suppressed LPS-induced neuroinflammation in the hippocampus and alleviated depression-like behaviors in mice. " 01/01/2018 - "This study investigated the anti-neuroinflammation molecular mechanisms exerted by scutellarin in LPS-induced BV-2 cells. " 06/30/2011 - "Together, the present study reported the anti-inflammatory activity of Scutellarin in microglial cells along with their underlying molecular mechanisms, and suggested Scutellarin might have therapeutic potential for various microglia mediated neuroinflammation."

Related Drugs and Biologics

1.	Antioxidants
2.	Amyloid (Amyloid Fibrils)
3.	Proteins (Proteins, Gene)
4.	Retinaldehyde (Retinal)
5.	Catenins
6.	Flavonoids
7.	breviscapine
8.	Messenger RNA (mRNA)
9.	Esters
10.	Calcium-Calmodulin-Dependent Protein Kinase Type 2

Related Therapies and Procedures

1.	Oral Administration
2.	Intraperitoneal Injections
3.	Immunotherapy
4.	Therapeutics
5.	Surgical Instruments (Clip)